For a glaucoma patient . . .

Maximum efficacy is the first priority

Short-term hyperemia doesn't need to be a barrier when battling progression

New Gallup survey reveals patient concern over glaucomatous vision loss:

• Among glaucoma patients, 83% fear potential vision loss ¹
  
• Almost 4 out of 10 glaucoma patients report existing vision loss ¹

• 92% responded that they preferred the most effective medication, even if it meant the possibility of a few weeks of red eyes ²
  • Only 8% responded that they wanted a less effective medication that did not cause red eyes ²
    
  • Only 4% of patients said they would discontinue a medication if it caused temporary red eyes ²
• Three times as many patients changed doctors out of concern over IOP reduction than medication side effects ²
  

• 99% of patients agree increased IOP reduction is worth managing hyperemia ³

Facts about LUMIGAN compliance reveal patient resolve

LEED data from a community-based, 2-month, open-label, multicenter, naturalistic trial involving 1428 sites throughout the United States and Puerto Rico. Patients with glaucoma or ocular hypertension who needed additional IOP lowering or who were intolerant of other glaucoma medication were placed on bimatoprost therapy (alone or in combination with other drugs at the physician's discretion).

EPIC data collected from a product experience trial of 238 patients with glaucoma or ocular hypertension. Patients were asked medication-related questions ranging from prior medications used, therapy satisfaction, and current knowledge of disease state. Intraocular pressure (IOP) measurements were also taken at baseline and at a follow-up visit approximately 6 weeks later.

Why let short-term hyperemia keep a patient from the long-term benefits of IOP reduction?